Login / Signup

Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.

Weiguang XueParanjoy SahariaEmma GrayShoghag Khoudigian-SinaniVéronique GaudetMartin BarbeauKim Papp
Published in: Journal of cutaneous medicine and surgery (2020)
Brodalumab 210 mg has efficacy superior to most biologic agents for moderate-to-severe plaque psoriasis in Canada.
Keyphrases
  • systematic review
  • coronary artery disease
  • high intensity
  • early onset
  • rheumatoid arthritis
  • drug induced
  • network analysis